Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $50.0 million
Deal Type : Funding
Tessera Therapeutics Invests in Sickle Cell Disease in Vivo Genetic Treatment
Details : The funding will be used to support the development of Tessera's in vivo program for sickle cell disease program into the clinic.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 18, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $50.0 million
Deal Type : Funding